**Core tip:** We detected seven excision repair cross complementing group 5 (*ERCC5*) single nucleotide polymorphisms (SNPs) and a glutathione S-transferase pi1 (*GSTP1*) SNP using the Sequenom MassARRAY platform in a Chinese population and used them to investigate their interactions and their effects on atrophic gastritis and gastric cancer risk. The results showed a multifarious interaction between the DNA repair gene *ERCC5* SNPs (rs2094258 and rs873601) and the metabolic gene *GSTP1* rs1695. In addition, the cumulative effect of one pairwise interaction (*ERCC5* rs873601-*GSTP1* rs1695) was associated with an increased atrophic gastritis risk in the case of negative *H. pylori* status when the modification effect of *H. pylori* infection was evaluated.

INTRODUCTION
============

In light of the study of gastric cancer (GC) pathogenesis, there is increasing evidence to suggest that the interactions between various inherited susceptibility genes may affect the risk of GC development in individuals\[[@B1]\]. Single nucleotide polymorphisms (SNPs), as one of the most general forms of genetic variation, play a key role in predicting cancer risk in individuals and are widely applied to study tumor incidence and prognostic evaluation. However, they are inadequately utilized for studies of various genes in intricate diseases such as cancer\[[@B2]\], and the presently investigated polymorphisms for each single gene may not entirely reveal a definite phenotype\[[@B1]\]. Some studies have shown that interactions among genes are more significant than solitary genes in determining cancer susceptibility\[[@B3],[@B4]\].

Numerous epidemiological studies have shown that inherited polymorphisms involved in xenobiotic metabolism and DNA repair are related to GC\[[@B1],[@B5]\]. These genes are acknowledged as risk-modifier indicators, especially those whose allelic polymorphisms are accountable for the repair of oxidative stress induced DNA damage and/or the impaired metabolism of exogenous carcinogens. Excision repair cross complementing group 5 (*ERCC5*) is a critical element of the nucleotide excision repair (NER) pathway, and the *ERCC5* gene is mapped to a region on chromosome 13q33 and comprises 15 exons\[[@B6]\]. It encodes a structure-specific endonuclease that has multiple functions during NER\[[@B7]\]. Its main role is to identify and shear damage to the DNA chain 3' terminus\[[@B8]\]. Its gene mutation may lead to abnormal cell proliferation and differentiation and increased cancer susceptibility. SNPs of *ERCC5* linked with GC susceptibility have been reported, including rs2094258, rs751402, rs2296147, rs1047768, rs873601, rs2227869, and rs17655\[[@B6],[@B9]-[@B15]\]. We previously analyzed six SNPs of the *ERCC5* gene in 2686 subjects from northern China and found that the selected polymorphisms of the ERCC5 gene were not significantly associated with atrophic gastritis (AG)/GC risk\[[@B16]\]. Glutathione S-transferase (GST) is an important member of the phase II metabolic enzymes, including GSTM1, GSTT1, and glutathione S-transferase pi1 (GSTP1)\[[@B17]\], which can affect detoxification processes and increase individual susceptibility to cancers\[[@B18]\]. The GSTP1 Ile105Val polymorphism produces the amino acid replacement of Ile (105) with Val *via* the change of A (Ile) to G (Val) in exon 5, which diminishes enzyme catalytic activity\[[@B6]\] and indirectly stimulates DNA repair and protection of the cell genome\[[@B7],[@B8]\]. Our previous study also identified SNP rs1695 in *GSTP1*, which appears to drastically change the susceptibility of individuals to GC\[[@B9]\]. This finding is consistent with previous studies\[[@B10],[@B11]\].

Although some studies have found that *ERCC5* SNPs and *GSTP1* polymorphisms were related to GC risk, there are limited data on the effects of gene-gene interactions, and some results are equivocal\[[@B12],[@B13]\]. Additionally, given the vital impact of environmental factors on the susceptibility to GC and our previous findings regarding gene interaction and environmental factors\[[@B4],[@B14],[@B16]\], we explored possible two-dimensional gene interactions among inherited polymorphisms in the DNA repair gene *ERCC5* (rs1047768, rs2094258, rs2228959, rs4150291, rs4150383, rs751402, and rs873601) and the metabolic gene *GSTP1* (rs1695), as well as the three-dimensional interactions between SNP-SNP and environmental factors in diverse stages of gastric carcinogenesis to assess the possibility of predicting GC risk and the identification of a combination of biomarkers for precancerosis and GC.

MATERIALS AND METHODS
=====================

Study population
----------------

In all, 1705 subjects were included in the present study, comprising 621 healthy controls, 634 cases of AG, and 450 cases of GC. All registered individuals originated from a Screening Program for Gastric Diseases or hospitals in Zhuanghe and Shenyang of Liaoning Province, China between 2002 and 2013, as previously described\[[@B16]\]. Metadata for every participant was collected using a standardized questionnaire survey and stored in a spreadsheet, including gender, age, history of illness, status of smoking, and alcohol consumption. Every participant signed a written informed consent from, according to the Declaration of Helsinki and its later revision. We collected peripheral venous blood from all participants, and experienced endoscopists simultaneously performed gastroscopic examination. All subjects received histopathological diagnosis according to the updated Sydney System\[[@B15]\] and the World Health Organization criteria, independently, by two gastrointestinal pathologists. This project was approved by the Human Ethics Review Committee of China Medical University (Shenyang, China).

SNP selection and genotyping assay
----------------------------------

Briefly, as described in our previous study\[[@B16]\], we extracted *ERCC5* genotype data from the HapMap Chinese Han Beijing population (<http://www.HapMap.org>). Tag SNPs were derived from pairwise linkage disequilibrium information to maximally capture (*r*^2^ \> 0.8) common or rare variants \[minor allele frequency (MAF) \> 0.05\] using Haploview 4.2 (<http://www.broadinstitute.org/mpg/haploview>). FastSNP Search was used to predict potential SNP function. Finally, a total of seven *ERCC5* SNPs (rs1047768, rs2094258, rs2228959, rs4150291, rs4150383, rs751402, and rs873601) were chosen in this study. In addition, *GSTP1* rs1695 was selected according to our previous study and literature references\[[@B9]-[@B11]\]. Genomic DNA was isolated from blood samples using a routine phenol-chloroform method and then diluted to working concentrations (50 ng/μL) for genotyping. Samples were placed randomly in 384-well plates and blinded for disease status. Selected SNP genotyping was performed using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, United States) according to the manufacturer's instructions\[[@B16]\]. The average genotyping rate was 99.3% and the results of all duplicated samples were 100% consistent.

Assessment of Helicobacter pylori serology
------------------------------------------

*Helicobacter pylori* (*H. pylori*) immunoglobulin G levels was tested using an enzyme-linked immunosorbent assay (ELISA kit, Biohit, Helsinki, Finland) according to the manufacturer's instructions, as previously described\[[@B16]\]. *H. pylori* positivity was defined as a numerical reading exceeding 34 enzyme immune units.

Statistical analysis
--------------------

Statistical analyses in the study were completed by applying SPSS 17.0 software (SPSS Inc., Chicago, IL, United States). We used the χ^2^ test to calculate the differences in demographic characteristics and genotypes between cases and controls. The two- or three-dimensional interaction effects among SNP-SNP with or without environmental factors were estimated using multivariate logistic regression models. General linear regression modeling was used to assess the trends with an increasing number of mutation genotypes in the cumulative effect. Associations were evaluated by odds ratios (ORs) and 95% confidence intervals (CIs) adjusted by sex, age, and *H. pylori* infection status except for being stratified by *H. pylori* infection status. Two-sided *P-*values \< 0.05 were considered statistically significant.

RESULTS
=======

Demographic and geographic characteristics
------------------------------------------

The distribution characteristics of gender, age, and *H. pylori* infection status of all participants are shown in Table [1](#T1){ref-type="table"}. No significant differences were found in the gender or age distribution among the case and control groups. The study subjects consisted of 634 AG patients, 450 GC patients, and two control groups, including 620 and 535 for AG and GC cases, matched by gender and age, respectively. Additionally, there were significantly higher *H. pylori* infection rates (59.5% and 49.6%, respectively) in the AG and GC groups compared to the two matched control groups (27.1% and 26.7%, respectively, *P* \< 0.001).

###### 

Baseline characteristics of the subjects *n* (%)

  **Variable**                   **AG *vs* CON**   **GC *vs* CON**                
  ------------------------------ ----------------- ----------------- ------------ -------------
                                 *n* = 620         *n* = 634         *n* = 535    *n* = 450
  Gender                         *P* = 0.492       *P* = 0.588                    
  Male                           362 (58.4)        358 (56.5)        363 (67.9)   298 (66.2)
  Female                         258 (41.6)        276 (43.5)        172 (32.1)   152 (33.8)
  Age                            *P* = 0.845       *P* = 0.235                    
  mean ± SD                      54.7 ± 9.1        54.8 ± 9.0        55.6 ± 9.2   56.3 ± 10.1
  Median                         54                55                56           57
  Range                          17-85             16-82             17-85        26-84
  *H. pylori* infection status   *P* \< 0.001      *P* \< 0.001                   
  Positive                       168 (27.1)        377 (59.5)        143 (26.7)   223 (49.6)
  Negative                       452 (72.9)        257 (40.5)        392 (73.3)   227 (50.4)

AG: Atrophic gastritis; GC: Gastric cancer; CON: Controls.

Pairwise interactions between the ERCC5 SNPs and GSTP1 rs1695 polymorphism
--------------------------------------------------------------------------

We primarily examined SNP-SNP two-dimensional interaction effects in the main effect analysis using a full-factor model. Two pairwise SNP combinations were found that could affect AG risk, but no pairwise combination was found in relation to GC risk. The results indicated that the *ERCC5* rs2094258 and rs873601 polymorphisms with *GSTP1* rs1695 polymorphism could engender interaction effects for AG risk (*P*~interactio~*~n~* = 0.008 and 0.043 respectively, Table [2](#T2){ref-type="table"}). The *ERCC5* rs2094258-*GSTP1* rs1695 SNP pair demonstrated an antagonistic effect, while ERCC5 rs873601-GSTP1 rs1695 showed a synergistic effect on AG risk (OR = 0.51 and1.79, respectively, Table [2](#T2){ref-type="table"}). No significant differences were observed among other SNP-SNP interactions (*P* \> 0.05).

###### 

Impact of two-way interactions between *ERCC5* polymorphisms and *GSTP1* rs1695 on risk of atrophic gastritis and gastric cancer^1^

  **Gene**                **Genotype**   **Number of participants**   **GSTP1 rs1695**                                                              
  ----------------------- -------------- ---------------------------- ------------------------------ ------------------- -------------------------- -------------------
  AG *vs* CON                                                                                                                                       
  (*n* = 634 *vs* 620 )                                                                                                                             
  *ERCC5* rs1047768       TT             No. of cases/controls        231/200                        124/116             338/307                    17/9
                                         OR (95%CI)                   1 (Ref.)                       0.93 (0.68-1.27)    1 (Ref.)                   1.72 (0.75-3.91)
                          TC + CC        No. of cases/controls        177/188                        102/116             270/289                    9/15
                                         OR (95%CI)                   0.82 (0.62-1.08)               0.76 (0.55-1.06)    0.85 (0.68-1.07)           0.55 (0.24-1.26)
                                                                      *P*~interaction~ = 0.317                           *P*~interaction~ = 0.683   
                                                                      Interaction index = 0.88                           Interaction index = 1.13   
                          TT + TC        No. of cases/controls        376/345                        207/214             559/538                    24/21
                                         OR (95%CI)                   1 (Ref.)                       0.89 (0.70-1.13)    1 (Ref.)                   1.10 (0.61-2.00)
                          CC             No. of cases/controls        32/43                          19/18               49/58                      2/3
                                         OR (95%CI)                   0.68 (0.42-1.10)               0.97 (0.50-1.87)    0.81 (0.55-1.21)           0.64 (0.11-3.86)
                                                                      *P*~interaction~ = 0.296                           *P*~interaction~ = 0.531   
                                                                      Interaction index = 0.88                           Interaction index = 0.88   
  *ERCC5* rs2094258       GG             No. of cases/controls        132/162                        93/84               214/234                    11/12
                                         OR (95%CI)                   1 (Ref.)                       1.36 (0.94-1.98)    1 (Ref.)                   1.00 (0.43-2.32)
                          GA + AA        No. of cases/controls        276/226                        133/148             394/362                    15/12
                                         OR (95%CI)                   1.50 (1.12-2.00)               1.10 (0.79-1.53)    1.19 (0.94-1.50)           1.37 (0.63-2.99)
                                                                      ***P*~interaction~ = 0.008**                       *P*~interaction~ = 0.842   
                                                                      **Interaction index = 0.51**                       Interaction index = 1.13   
                          GG + GA        No. of cases/controls        337/328                        195/204             508/510                    24/22
                                         OR (95%CI)                   1 (Ref.)                       0.93 (0.73-1.19)    1 (Ref.)                   1.10 (0.61-1.98)
                          AA             No. of cases/controls        71/60                          31/28               100/86                     2/2
                                         OR (95%CI)                   1.15 (0.79-1.68)               1.08 (0.63-1.84)    1.17 (0.85-1.60)           1.00 (0.14-7.15)
                                                                      *P*~interaction~ = 0.594                           *P*~interaction~ = 0.620   
                                                                      Interaction index = 0.83                           Interaction index = 0.58   
  *ERCC5* rs2228959       CC             No. of cases/controls        371/346                        198/215             548/539                    21/22
                                         OR (95%CI)                   1 (Ref.)                       0.86 (0.67-1.09)    1 (Ref.)                   0.94 (0.51-1.73)
                          CA + AA        No. of cases/controls        37/42                          28/17               60/57                      5/2
                                         OR (95%CI)                   0.82 (0.52-1.31)               1.54 (0.83-2.86)    1.04 (0.71-1.52)           2.46 (0.48-12.73)
                                                                      *P*~interaction~ = 0.103                           *P*~interaction~ = 0.435   
                                                                      Interaction index = 2.00                           Interaction index = 2.11   
                          CC + CA        No. of cases/controls        408/383                        224/231             606/590                    26/24
                                         OR (95%CI)                   1 (Ref.)                       0.91 (0.72-1.15)    1 (Ref.)                   1.06 (0.60-1.86)
                          AA             No. of cases/controls        0/5                            2/1                 2/6                        0/0
                                         OR (95%CI)                   NA                             1.88 (0.17-20.79)   0.32 (0.07-1.61)           NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = 0.720   
                                                                      Interaction index = NA                             Interaction index = 1.12   
  *ERCC5* rs4150291       AA             No. of cases/controls        347/332                        193/205             517/516                    23/21
                                         OR (95%CI)                   1 (Ref.)                       0.90 (0.70-1.15)    1 (Ref.)                   1.09 (0.60-2.00)
                          AT + TT        No. of cases/controls        61/56                          33/27               91/80                      3/3
                                         OR (95%CI)                   1.04 (0.70-1.54)               1.17 (0.69-1.99)    1.14 (0.82-1.57)           1.00 (0.20-4.97)
                                                                      *P*~interaction~ = 0.667                           *P*~interaction~ = 0.679   
                                                                      Interaction index = 1.17                           Interaction index = 0.68   
                          AA + AT        No. of cases/controls        406/382                        225/232             605/590                    26/24
                                         OR (95%CI)                   1 (Ref.)                       0.91 (0.73-1.15)    1 (Ref.)                   1.06 (0.60-1.86)
                          TT             No. of cases/controls        2/6                            1/0                 3/6                        0/0
                                         OR (95%CI)                   0.31 (0.06-1.56)               NA                  0.49 (0.12-1.96)           NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = 0.703   
                                                                      Interaction index = NA                             Interaction index = 1.12   
  *ERCC5* rs4150383       GG             No. of cases/controls        365/344                        197/202             539/526                    23/20
                                         OR (95%CI)                   1 (Ref.)                       0.92 (0.72-1.18)    1 (Ref.)                   1.12 (0.61-2.07)
                          GA + AA        No. of cases/controls        43/44                          29/30               69/70                      3/4
                                         OR (95%CI)                   0.92 (0.59-1.44)               0.91 (0.54-1.55)    0.96 (0.68-1.37)           0.73 (0.16-3.29)
                                                                      *P*~interaction~ = 0.720                           *P*~interaction~ = 0.894   
                                                                      Interaction index = 1.15                           Interaction index = 1.12   
                          GG + GA        No. of cases/controls        406/387                        226/231             606/594                    26/24
                                         OR (95%CI)                   1 (Ref.)                       0.93 (0.74-1.17)    1 (Ref.)                   1.06 (0.60-1.87)
                          AA             No. of cases/controls        2/1                            0/1                 2/2                        0/0
                                         OR (95%CI)                   1.91 (0.17-21.11)              NA                  0.98 (0.14-6.98)           NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = 0.695   
                                                                      interaction index = NA                             interaction index = 1.13   
  *ERCC5* rs751402        CC             No. of cases/controls        191/173                        97/104              281/266                    7/11
                                         OR (95%CI)                   1 (Ref.)                       0.85 (0.60-1.19)    1 (Ref.)                   0.60 (0.23-1.58)
                          CT + TT        No. of cases/ controls       203/198                        124/118             308/303                    19/13
                                         OR (95%CI)                   0.93 (0.70-1.23)               0.95 (0.69-1.32)    0.96 (0.76-1.21)           1.38 (0.67-2.86)
                                                                      *P*~interaction~ = 0.196                           *P*~interaction~ = 0.109   
                                                                      Interaction index = 1.39                           Interaction index = 2.84   
                          CC + CT        No. of cases/ controls       355/324                        193/196             526/500                    22/20
                                         OR (95%CI)                   1 (Ref.)                       0.90 (0.70-1.15)    1 (Ref.)                   1.05 (0.56-1.94)
                          TT             No. of cases/ controls       39/47                          28/26               63/69                      4/4
                                         OR (95%CI)                   0.76 (0.48-1.19)               0.98 (0.56-1.71)    0.87 (0.60-1.25)           0.95 (0.24-3.81)
                                                                      *P*~interaction~ = 0.488                           *P*~interaction~ = 0.886   
                                                                      Interaction index = 1.31                           Interaction index = 1.13   
  *ERCC5* rs873601        GG             No. of cases/ controls       126/109                        57/59               178/165                    5/3
                                         OR (95%CI)                   1 (Ref.)                       0.84 (0.54-1.30)    1 (Ref.)                   1.55 (0.36-6.57)
                          GA + AA        No. of cases/ controls       282/279                        169/173             430/431                    21/21
                                         OR (95%CI)                   0.87 (0.64-1.19)               0.85 (0.61-1.18)    0.93 (0.72-1.19)           0.93 (0.49-1.76)
                                                                      *P*~interaction~ = 0.197                           *P*~interaction~ = 0.770   
                                                                      Interaction index = 1.44                           Interaction index = 0.78   
                          GG + GA        No. of cases/ controls       321/279                        167/177             473/441                    15/15
                                         OR (95%CI)                   1 (Ref.)                       0.82 (0.63-1.07)    1 (Ref.)                   0.93 (0.45-1.93)
                          AA             No. of cases/ controls       87/109                         59/55               135/155                    11/9
                                         OR (95%CI)                   0.69 (0.50-0.96)               0.93 (0.62-1.39)    0.81 (0.62-1.06)           1.14 (0.47-2.78)
                                                                      ***P*~interaction~ = 0.043**                       *P*~interaction~ = 0.488   
                                                                      **Interaction index = 1.79**                       Interaction index = 1.55   
  GC *vs* CON                                                                                                                                       
  (*n* = 450 *vs* 535 )                                                                                                                             
  *ERCC5* rs1047768       TT             No. of cases/ controls       142/162                        78/105              204/259                    16/8
                                         OR (95%CI)                   1 (Ref.)                       0.85 (0.59-1.23)    1 (Ref.)                   2.54 (1.07-6.05)
                          TC + CC        No. of cases/ controls       128/164                        102/104             211/255                    19/13
                                         OR (95%CI)                   0.89 (0.65-1.23)               1.12 (0.79-1.59)    1.05 (0.81-1.36)           1.86 (0.89-3.85)
                                                                      *P*~interaction~ = 0.101                           *P*~interaction~ = 0.594   
                                                                      interaction index = 1.56                           interaction index = 0.73   
                          TT + TC        No. of cases/ controls       247/292                        158/193             374/467                    31/18
                                         OR (95%CI)                   1 (Ref.)                       0.97 (0.74-1.27)    1 (Ref.)                   2.15 (1.18-3.91)
                          CC             No. of cases/ controls       23/24                          22/16               41/47                      4/3
                                         OR (95%CI)                   0.80 (0.46-1.39)               1.63 (0.84-3.16)    1.09 (0.70-1.69)           1.67 (0.37-7.49)
                                                                      *P*~interaction~ = 0.115                           *P*~interaction~ = 0.640   
                                                                      Interaction index = 2.07                           Interaction index = 0.66   
  *ERCC5* rs2094258       GG             No. of cases/ controls       110/131                        66/77               165/197                    11/11
                                         OR (95%CI)                   1 (Ref.)                       1.02 (0.67-1.55)    1 (Ref.)                   1.19 (0.51-2.82)
                          GA + AA        No. of cases/ controls       160/195                        114/132             250/317                    24/10
                                         OR (95%CI)                   0.98 (0.70-1.36)               1.03 (0.72-1.47)    0.94 (0.72-1.23)           2.87 (1.33-6.17)
                                                                      *P*~interaction~ = 0.923                           *P*~interaction~ = 0.134   
                                                                      Interaction index = 0.97                           Interaction index = 2.47   
                          GG + GA        No. of cases/ controls       226/275                        158/185             352/441                    32/19
                                         OR (95%CI)                   1 (Ref.)                       1.04 (0.79-1.37)    1 (Ref.)                   2.11 (1.18-3.79)
                          AA             No. of cases/ controls       44/51                          22/24               63/73                      3/2
                                         OR (95%CI)                   1.05 (0.68-1.63)               1.12 (0.61-2.04)    1.08 (0.75-1.56)           1.88 (0.31-11.31)
                                                                      *P*~interaction~ = 0.801                           *P*~interaction~ = 0.834   
                                                                      Interaction index = 0.90                           Interaction index = 0.81   
  *ERCC5* rs2228959       CC             No. of cases/ controls       247/295                        164/194             380/470                    31/19
                                         OR (95%CI)                   1 (Ref.)                       1.01 (0.77-1.32)    1 (Ref.)                   2.02 (1.12-3.63)
                          CA + AA        No. of cases/ controls       23/31                          16/15               35/44                      4/2
                                         OR (95%CI)                   0.89 (0.50-1.56)               1.27 (0.62-2.63)    0.98 (0.62-1.57)           2.47 (0.45-13.58)
                                                                      *P*~interaction~ = 0.491                           *P*~interaction~ = 0.813   
                                                                      Interaction index = 1.40                           Interaction index = 1.26   
                          CC + CA        No. of cases/ controls       268/322                        180/208             413/509                    35/21
                                         OR (95%CI)                   1 (Ref.)                       1.04 (0.80-1.35)    1 (Ref.)                   2.05 (1.18-3.58)
                          AA             No. of cases/ controls       2/4                            0/1                 2/5                        0/0
                                         OR (95%CI)                   0.60 (0.11-3.31)               NA                  0.49 (0.10-2.55)           NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = NA      
                                                                      Interaction index = NA                             Interaction index = NA     
  *ERCC5* rs4150291       AA             No. of cases/ controls       222/276                        143/182             338/440                    27/18
                                         OR (95%CI)                   1 (Ref.)                       0.98 (0.74-1.29)    1 (Ref.)                   1.95 (1.06-3.61)
                          AT + TT        No. of cases/ controls       48/50                          37/27               77/74                      8/3
                                         OR (95%CI)                   1.19 (0.77-1.84)               1.70 (1.01-2.89)    1.36 (0.96-1.92)           3.47 (0.91-13.18)
                                                                      *P*~interaction~ = 0.385                           *P*~interaction~ = 0.818   
                                                                      Interaction index = 1.37                           Interaction index = 1.20   
                          AA + AT        No. of cases/ controls       267/321                        177/209             410/509                    34/21
                                         OR (95%CI)                   1 (Ref.)                       1.02 (0.79-1.32)    1 (Ref.)                   2.01 (1.15-3.52)
                          TT             No. of cases/ controls       3/5                            3/0                 5/5                        1/0
                                         OR (95%CI)                   0.72 (0.17-3.05)               NA                  1.24 (0.36-4.32)           NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = NA      
                                                                      Interaction index = NA                             Interaction index = NA     
  *ERCC5* rs4150383       GG             No. of cases/ controls       237/288                        168/180             373/451                    32/17
                                         OR (95%CI)                   1 (Ref.)                       1.13 (0.86-1.49)    1 (Ref.)                   2.28 (1.24-4.16)
                          GA + AA        No. of cases/ controls       33/38                          12/29               42/63                      3/4
                                         OR (95%CI)                   1.06 (0.64-1.74)               0.50 (0.25-1.01)    0.81 (0.53-1.22)           0.91 (0.20-4.08)
                                                                      *P*~interaction~ = 0.060                           *P*~interaction~ = 0.497   
                                                                      Interaction index = 0.43                           Interaction index = 0.55   
                          GG + GA        No. of cases/ controls       270/325                        180/208             415/512                    35/21
                                         OR (95%CI)                   1 (Ref.)                       1.04 (0.81-1.35)    1 (Ref.)                   2.06 (1.18-3.59)
                          AA             No. of cases/ controls       0/1                            0/1                 0/2                        0/0
                                         OR (95%CI)                   NA                             NA                  NA                         NA
                                                                      *P*~interaction~ = NA                              *P*~interaction~ = NA      
                                                                      Interaction index = 0.90                           Interaction index = NA     
  *ERCC5* rs751402        CC             No. of cases/ controls       114/149                        82/90               180/229                    16/10
                                         OR (95%CI)                   1 (Ref.)                       1.19 (0.81-1.75)    1 (Ref.)                   2.04 (0.90-4.59)
                          CT + TT        No. of cases/ controls       142/161                        89/109              212/259                    19/11
                                         OR (95%CI)                   1.15 (0.83-1.61)               1.07 (0.74-1.55)    1.04 (0.80-1.36)           2.20(1.02-4.74)
                                                                      *P*~interaction~ = 0.453                           *P*~interaction~ = 0.945   
                                                                      Interaction index = 0.81                           Interaction index = 0.96   
                          CC + CT        No. of cases/ controls       225/275                        156/174             348/432                    33/17
                                         OR (95%CI)                   1 (Ref.)                       1.10 (0.83-1.45)    1 (Ref.)                   2.41 (1.32-4.40)
                          TT             No. of cases/ controls       31/35                          15/25               44/56                      2/4
                                         OR (95%CI)                   1.08 (0.65-1.81)               0.73 (0.38-1.42)    0.98 (0.64-1.48)           0.62 (0.11-3.41)
                                                                      *P*~interaction~ = 0.409                           *P*~interaction~ = 0.241   
                                                                      Interaction index = 0.69                           Interaction index = 0.32   
                                         No. of cases/ controls       79/91                          55/53               122/141                    12/3
  *ERCC5* rs873601        GG             OR (95%CI)                   1 (Ref.)                       1.20 (0.74-1.94)    1 (Ref.)                   4.62 (1.28-16.76)
                                         No. of cases/ controls       191/235                        125/156             293/373                    23/18
                          GA + AA        OR (95%CI)                   0.94 (0.66-1.34)               0.92 (0.63-1.35)    0.91 (0.68-1.21)           1.48 (0.76-2.87)
                                                                      *P*~interaction~ = 0.901                           *P*~interaction~ = 0.217   
                                                                      Interaction index = 0.96                           Interaction index = 0.40   
                                         No. of cases/ controls       205/232                        139/156             317/375                    27/13
                          GG + GA        OR (95%CI)                   1 (Ref.)                       1.01 (0.75-1.36)    1 (Ref.)                   2.46 (1.25-4.84)
                                         No. of cases/ controls       65/94                          41/35               98/139                     8/8
                          AA             OR (95%CI)                   0.78 (0.54-1.13)               0.88 (0.56-1.37)    0.83(0.62-1.12)            1.18 (0.44-3.18)
                                                                      *P*~interaction~ = 0.477                           *P*~interaction~ = 0.384   
                                                                      Interaction index = 1.25                           Interaction index = 0.57   

^1^*P* for interaction, logistic regression adjusted for gender, age, and *H. pylori* infection status; Statistically significant associations were highlighted in bold (*P* \< 0.05). CON: Controls; AG: Atrophic gastritis; GC: Gastric cancer; NA: Not available; GSTP1: Glutathione S-transferase pi 1; ERCC5: Excision repair cross complementing group 5.

Epistatic effect of two-way interactions
----------------------------------------

We further investigated epistatic effects between pairs of *ERCC5* rs2094258 and rs873601 polymorphisms with *GSTP1* rs1695. For *ERCC5* rs2094258 and *GSTP1* rs1695, the AG/AA genotypes of rs2094258 and AA genotype of rs1695 were related to an increased risk of AG, but GA/GG genotypes of rs1695 were associated with a reduced risk of AG (OR = 1.523 and 0.678, respectively). For *ERCC5* rs873601 and *GSTP1* rs1695, AA genotype of rs873601 resulted in a reduced risk of AG, only in the presence of AA genotype of rs1695 (OR = 0.678) (Table [3](#T3){ref-type="table"}). These findings illustrated that *ERCC5* rs2094258 and rs873601, individually, had no main effect but did display epistatic interactions with *GSTP1* rs1695.

###### 

Epistatic effect of pair-wise interacting factors on the risk of atrophic gastritis and gastric cancer

  **Interacted pair-wise SNPs**                      **Comparison**                      **Subset**        **AG *vs* CON**           **GC *vs* CON**                                 
  -------------------------------------------------- ----------------------------------- ----------------- ------------------------- ------------------------- --------------------- ---------------------
  *ERCC5* rs2094258 interacted with *GSTP1* rs1695   *ERCC5* rs2094258 GG *vs* AG + AA   GSTP1 rs1695 AA   **0.006**                 **1.523 (1.125-2.062)**   0.948                 0.989 (0.704-1.388)
                                                     GSTP1 rs1695 GA + GG                0.205             0.766 (0.508-1.157)       0.820                     0.951 (0.619-1.462)   
  *GSTP1* rs1695 AA *vs* GA + GG                     ERCC5 rs2094258 GG                  0.148             1.343 (0.901-2.002)       0.808                     1.055 (0.685-1.625)   
                                                     ERCC5 rs2094258 AG + AA             **0.014**         **0.678 (0.497-0.926)**   0.799                     1.045 (0.745-1.465)   
  *ERCC5* rs873601 interacted with *GSTP1* rs1695    *ERCC5* rs873601 GA + GG *vs* AA    GSTP1 rs1695 AA   **0.025**                 **0.678 (0.483-0.952)**   0.148                 0.756 (0.517-1.105)
                                                     GSTP1 rs1695 GA + GG                0.380             1.230 (0.775-1.951)       0.872                     0.961 (0.592-1.560)   
  *GSTP1* rs1695 AA *vs* GA + GG                     ERCC5 rs873601 GA + GG              0.054             0.758 (0.571-1.005)       0.955                     0.991 (0.730-1.346)   
                                                     ERCC5 rs873601 AA                   0.226             1.356 (0.828-2.222)       0.542                     1.183 (0.690-2.027)   

All tests were adjusted by age, sex, and *H. pylori* infection. Statistically significant associations were highlighted in bold (*P* \< 0.05). GC: Gastric cancer; AG: Atrophic gastritis; CON: Controls; ERCC5: Excision repair cross complementing group 5; GSTP1: Glutathione S-transferase pi 1.

Cumulative effect of the interacting factors of ERCC5 SNPs-GSTP1 rs1695
-----------------------------------------------------------------------

We also investigated the cumulative effect among the interacting SNPs of *ERCC5* rs2094258 and rs873601 with *GSTP1* rs1695, but neither had a statistically significant relationship to AG risk (*P* \> 0.05, Table [4](#T4){ref-type="table"}). We further analyzed the cumulative effect of interacting SNPs modified by *H. pylori*. The *ERCC5* rs873601-*GSTP1* rs1695 SNP pair had significant differences in AG risk among the subgroups with negative *H. pylori* infection status (*P*~trend~ = 0.043). Moreover, AG risk was significantly reduced while one or two mutation genotypes were present (OR = 0.66, 95%CI: 0.37-1.16, and OR = 0.73, 95%CI: 0.53-1.02, respectively).

###### 

Cumulative effect of the interacting factors of ERCC5 SNPs-GSTP1 rs1696 on atrophic gastritis risk

  **No. of interacting genotypes**          **Total population**   ***H. pylori*-negative subpopulation**   ***H. pylori*-positive subpopulation**                                                                                       
  ----------------------------------------- ---------------------- ---------------------------------------- ---------------------------------------- --------- ------------------------ ------------------ -------- -------------------- ------------------
  ERCC5 rs2094258-GSTP1 rs1695 on AG risk                                                                                                                                                                                                
  0                                         132/162                                                         1 (Ref.)                                 57/115                             1 (Ref.)           75/47                         1 (Ref.)
  1                                         369/310                0.008                                    1.48 (1.11-1.98)                         216/79    0.125                    1.35 (0.92-1.97)   216/79   0.017                1.72 (1.10-2.69)
  2                                         133/148                0.782                                    1.05 (0.74-1.49)                         47/106    0.655                    0.90 (0.56-1.44)   86/42    0.363                1.270.76-2.14)
                                                                   *P*~trend~ = 0.528                                                                          *P*~trend~ = 0.720                                   *P*~trend~ = 0.349   
  ERCC5 rs873601-GSTP1 rs1695on AG risk                                                                                                                                                                                                  
  0                                         321/279                                                         1 (Ref.)                                 138/206                            1 (Ref.)           183/73                        1 (Ref.)
  1                                         254/286                0.013                                    0.73 (0.57-0.94)                         99/201    0.061                    0.73 (0.53-1.02)   155/85   0.090                0.72 (0.49-1.05)
  2                                         59/55                  0.670                                    0.911 (0.60-1.40)                        20/45     0.150                    0.66 (0.37-1.16)   39/10    0.241                1.57 (0.74-3.31)
                                                                   *P*~trend~ = 0.156                                                                          ***P*~trend~ = 0.043**                               *P*~trend~ = 0.907   

Adjusted by sex, age, and *H. pylori* infection;

Adjusted by sex and age. Statistically significant associations were highlighted in bold (*P* \< 0.05). CON: Controls; AG: Atrophic gastritis; ERCC5: Excision repair cross complementing group 5; GSTP1: Glutathione S-transferase pi 1.

Three-dimensional analysis of the effect of interactions of ERCC5 SNPs-GSTP1 rs1695-environmental factors on AG risk
--------------------------------------------------------------------------------------------------------------------

To explore the influence of environmental factors on the interaction, we further explored probable three-dimensional interactions among *ERCC5* SNPs (rs2094258 and rs873601), *GSTP1* rs1695, and environmental factors (smoking, alcohol consumption, and *H. pylori* infection status). We found no significant three-dimensional interactions with regard to AG risk (*P* \> 0.05, Supplementary Table [1](#T1){ref-type="table"}).

DISCUSSION
==========

GC is an outcome of the interaction between multiple genes and environmental factors and is considered a multistep and multifactor process involving different carcinogen metabolic and DNA repair pathways\[[@B19],[@B20]\]. Currently, researchers are concentrating more on the gene-gene interaction effect rather than a single-gene effect. In this study, we examined the possible interaction effect of DNA repair gene *ERCC5* SNPs and the metabolic detoxification gene *GSTP1* polymorphism. We first found new two-pair SNP interactions among *ERCC5* SNPs and the *GSTP1* polymorphism (*ERCC5* rs2094258-*GSTP1* rs1695 and *ERCC5* rs873601-GSTP1 rs1695), which could alter the susceptibility to AG compared to host genetic effects alone. Moreover, the cumulative effect resulting from two-way interaction of *ERCC5* rs873601-*GSTP1* rs1695 was shown to differ in a stratified analysis of *H. pylori* infection status. The change from no cumulative effect to significant difference in AG risk in the case of negative *H. pylori* status indicated that *H. pylori* infection status could modify the cumulative effect mentioned above for the interacting SNPs. Genetic polymorphisms may explain partial individual deviations in disease risk, but a more multifarious condition involving numerous gene-gene interactions and gene-environment characteristics must be mentioned.

A combination of SNPs would produce synergistic or antagonistic effects compared to an SNP, which could change the susceptibility to disease\[[@B21],[@B22]\]. Individually, two *ERCC5* SNPs (rs2094258 and rs873601; unpublished data) showed no effect on either AG or GC risk (*P* \> 0.05). However, our findings revealed a main effect on AG risk while these polymorphisms interacted with *GSTP1* rs1695 (*P*~interactio~*~n~ =* 0.008 and 0.043, respectively). The pairwise ERCC5 rs2094258-*GSTP1* rs1695 and *ERCC5* rs873601-GSTP1 rs1695 combinations had an OR of 0.51 and 1.79, respectively, for AG risk in the above two-way interaction analysis. In all, this evidence suggests that polymorphisms harbored in *ERCC5* (rs2094258 and rs873601) had a synergistic or antagonistic effect with *GSTP1* rs1695, which could alter the risk of an individual towards AG. According to the potential mechanism of SNP-SNP interactions, the *ERCC5* gene, as an NER pathway gene, may be responsible for repairing DNA damage from biological and environmental mutagens or regular cellular metabolism. In addition, *GSTP1* as an important phase II metabolizing xenobiotic enzyme might promote DNA damage repair through an exogenous metabolic detoxification pathway. When exogenous or endogenous carcinogens cause damage to DNA, the metabolic gene *GSTP1* removes some harmful substances through the detoxification effect and then promotes DNA damage repair to protect against carcinogenic progression. The DNA repair gene *ERCC5* can identify and incise a DNA wound on the 3' terminus to ensure reliable repair of DNA damage\[[@B23]\]. The interaction polymorphisms can produce a superposition or counteracting effect. This may partly explain the epigenetic heritability loss of precancerosis risk and suggests novel insight into the multifactorial etiology of AG risk with regard to DNA repair gene *ERCC5* and xenobiotic metabolic gene *GSTP1* pathways. However, further independent studies of the molecular mechanism of SNP-SNP interactions must be performed in the future.

The SNP-SNP interaction effect of the two genes was observed as epistasis in the absence of a significant main effect\[[@B24]\]. The epistasis was more pronounced than one sole susceptibility gene in terms of main effects, which embody the effect of multipart interaction\[[@B4]\]. Multiple studies have revealed a relationship between epistasis and cancer risk\[[@B25],[@B26]\]. Our previous findings also indicated epistasis by combining individual SNPs, which had no effect on disease risk at a single locus\[[@B4],[@B14]\]. In the present study, for *ERCC5* rs2094258 and *GSTP1* rs1695, the AG/AA genotype of rs2094258 and AA genotype of rs1695 were related to an increased risk of AG, but GA/GG genotypes of rs1695a were associated with a reduced risk of AG. For *ERCC5* rs873601 and *GSTP1* rs1695, AA genotype of rs873601 resulted in a reduced risk of AG, only in the presence of AA genotype of rs1695. Thus, there is still little direct evidence to reveal a specific functional association among the polymorphisms of *ERCC5* and *GSTP1*. In light of previous research findings, we hypothesized an interaction effect between the DNA repair gene and xenobiotic metabolism gene by various signal pathways, and our discoveries regarding the interactions of the DNA repair *ERCC5* gene and xenobiotic metabolism *GSTP1* gene pathways may reveal the above assumption. Further synthetic and functional research on these two gene pathways will be performed to assess the interaction effect of susceptibility genes that directly affect gastric carcinogenesis.

Gastric carcinogenesis is also affected by environmental factors, in addition to genetic factors. *H. pylori* is considered a class I carcinogen by the World Health Organization and displays carcinogenic effects mediated by poisonous components\[[@B27],[@B28]\]. Our previous studies have shown that the GSTP1 Val/Val genotype with smoking, alcohol consumption, or *H. pylori* IgG (+) could considerably increase AG and GC risk, and the NER SNPs (XPA rs2808668, DDB2 rs326222, rs3781619, rs830083, and XPC rs2607775) had interactive effects with alcohol consumption and smoking on AG or GC risk. In the present study, the cumulative effect was observed to be changed in subgroups with negative *H. pylori* infection status, which could imply an effect modification by *H. pylori* infection. Moreover, AG risk was significantly reduced, while one or two mutation genotypes were present (OR = 0.66 and 0.73, respectively). This suggested that *H. pylori* should be eliminated first for positive patients, which may be beneficial for reducing susceptibility to AG. However, we further analyzed the effect of three-dimensional interactions of the *ERCC5* SNPs (rs2094258 and rs873601)-*GSTP1* rs1695-environmental factors on the risk of AG, but no interaction effect was observed among them in terms of AG risk. This may be because our present sample size was relatively small, and some genotypes were scarce. In addition, there was a significant difference in *H. pylori* infection rates between the case groups and two matched control groups (*P* \< 0.001). Although we performed all tests with an adjustment for *H. pylori* infection status except for those stratified by *H. pylori*, it still may be a limitation of the study. Nevertheless, it suggested that environmental factors were indispensable, although they cannot cause cancer or precancerosis alone. Genetic susceptibility may play a vital role in gastric carcinogenesis. Further large-sample and comprehensive study of the function of environmental factors in SNP-SNP interactions of *ERCC5* and *GSTP1* is necessary and may partially remedy probable false-negative results in the study.

The present study has several limitations. First, even if our study included a relatively large sample, prospective studies consisting of larger-scale sample and multicenter surveys are necessary to validate the results of SNP-SNP interaction effects shown here. Second, since we only included one metabolic gene polymorphism (*GSTP1* rs1695) of the GSTs in this study, further studies should involve other functional tagSNPs, such as GSTM1 and/or GSTT1, which should participate in SNP-SNP interactions between the DNA repair gene and xenobiotic metabolism gene pathways. In addition, the functions and mechanisms of the mentioned SNPs of the *ERCC5* gene and *GSTP1* gene pathways were not investigated and will require additional functional and molecular experiments to clarify.

In conclusion, we found for the first time that two pairwise interacting DNA repair gene *ERCC5* SNPs (rs2094258 and rs873601) and metabolic gene GSTP1 rs1695 polymorphism combinations were related to increased or reduced AG risk. Moreover, the results also demonstrated a significant difference in the cumulative effect in the *H. pylori*-negative subgroup on AG risk. The conclusions inferred from the present study about the effect of interactions between genetic polymorphisms may be conductive to proposing further studies to discover gene-gene interactions between DNA repair genes with xenobiotic metabolic gene pathways in gastric carcinogenesis.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Previous studies suggested that the interactions between various inherited susceptibility genes may affect carcinogenesis in individuals. Single nucleotide polymorphisms (SNPs) are widely applied to the research of tumor incidence and prognostic evaluation.

Research motivation
-------------------

We aimed to assess gene interactions amongst inherited polymorphisms between DNA repair gene excision repair cross complementing group 5 (*ERCC5*) SNPs and glutathione S-transferase pi1 (*GSTP1*) rs1695 to explore their possibility of predicting gastric cancer (GC) risk and identify combination biomarkers for precancerosis and GC.

Research objectives
-------------------

The objective was to investigate the impact of interactions of the DNA repair gene *ERCC5* with metabolic gene *GSTP1* on atrophic gastritis (AG) and GC risk.

Research methods
----------------

Seven *ERCC5* SNPs (rs1047768, rs2094258, rs2228959, rs4150291, rs4150383, rs751402, and rs873601) and *GSTP1* rs1695 SNP were detected using the Sequenom MassARRAY platform in 450 GC patients, 634 AG cases, and 621 healthy control subjects in a Chinese population.

Research results
----------------

Two pairwise combinations (*ERCC5* rs2094258 and rs873601 with *GSTP1* rs1695) influenced AG risk, and the *ERCC5* rs2094258-GSTP1 rs1695 SNP pair demonstrated an antagonistic effect while ERCC5 rs873601-GSTP1 rs1695 shown a synergistic effect on AG risk. When the effect modification of *Helicobacter pylori* (*H. pylori*) infection was evaluated, the cumulative effect of one aforementioned pairs-way interaction (ERCC5 rs873601-GSTP1 rs1695) showed a risk in the case of negative status of *H. pylori* infection.

Research conclusions
--------------------

DNA repair gene ERCC5 SNPs (rs2094258 and rs873601) and metabolic gene GSTP1 rs1695 polymorphism combinations were related to an increased or reduced AG risk. Moreover, the results also demonstrated a significant difference in the cumulative effect on AG risk in the *H. pylori*-negative subgroup.

Research perspectives
---------------------

The interaction effects between genetic polymorphisms may be conductive to proposing further studies to discover gene-gene interactions between DNA repair genes and xenobiotic metabolic genes in gastric carcinogenesis.
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